Moderna (WBO:MRNA) Construction In Progress : €789 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Moderna Construction In Progress?

Moderna's quarterly construction in progress increased from Jun. 2023 (€535 Mil) to Sep. 2023 (€675 Mil) and increased from Sep. 2023 (€675 Mil) to Dec. 2023 (€789 Mil).

Moderna's annual construction in progress increased from Dec. 2021 (€188 Mil) to Dec. 2022 (€265 Mil) and increased from Dec. 2022 (€265 Mil) to Dec. 2023 (€789 Mil).

Moderna Construction In Progress Historical Data

The historical data trend for Moderna's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Construction In Progress Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

2.90

28.77

187.62

265.26

788.62

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Construction In Progress	Get a 7-Day Free Trial															265.26	345.58	535.34	674.64	788.62

Moderna Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.